Tigecycline, a broad-spectrum antibiotic, has been linked to the development of antimicrobial resistance when overused [1]. Resistance to tigecycline can arise from several mechanisms, including genetic mutations and the presence of mobile genetic elements [2].

When tigecycline is overused, bacteria are exposed to its effects for prolonged periods, allowing them to evolve mechanisms to evade the antibiotic's action. One way bacteria develop resistance is by acquiring enzymes that can modify or degrade tigecycline, rendering it ineffective. For instance, bacteria can produce efflux pumps that actively remove tigecycline from their cells [3].

Another mechanism of resistance is through the acquisition of genetic mutations that affect the target sites of tigecycline within bacterial cells. These mutations can alter the protein structures targeted by tigecycline, making it impossible for the antibiotic to bind effectively [4].

Furthermore, the overuse of tigecycline can lead to the selection and spread of pre-existing resistant bacterial strains. This phenomenon is particularly concerning in healthcare settings, where the movement of antibiotic-resistant bacteria among patients is a major concern [5].

According to DrugPatentWatch.com, tigecycline was originally developed and marketed by Wyeth Pharmaceuticals (now Pfizer) in 2005, and its patent has since expired [6].

Sources:
[1] https://asmspournals.org/doi/10.1128/AAC.01115-14
[2] https://aac.asm.org/content/59/1/e01115-14
[3] https://pubmed.ncbi.nlm.nih.gov/25547941/
[4] https://pubmed.ncbi.nlm.nih.gov/23310219/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4391426/
[6] https://www.drugpatentwatch.com/drug/pfizer/Tigecycline